Introduction
============

The compound data sets reported in our original article ^[@ref-1]^ and the new data sets presented herein have resulted from research in the chemoinformatics and medicinal chemistry area and have mostly been generated from public domain repositories of compound structures and activity data. In addition, software tools made publicly available have also been developed in our laboratory ^[@ref-1]^. Data sets reported in the scientific literature in the context of computational method development and evaluation are often not publicly available, which limits the reproducibility of computational investigations and comparisons of different computational methods. We believe that it is important to provide such data to the scientific community to further improve the transparency and credibility of computational studies and support method development. In addition to the data sets designed for the development and evaluation of computational methods, we also make available data sets that were generated as a resource and knowledge base for medicinal chemistry applications. Our data sets and tools are provided via the ZENODO platform ( <https://zenodo.org/>) to ensure easy and stable access.

Materials and methods
=====================

The data sets reported herein were predominantly generated from [ChEMBL](https://www.ebi.ac.uk/chembl/) ^[@ref-2],\ [@ref-3]^, [BindingDB](http://www.bindingdb.org/bind/index.jsp) ^[@ref-4]^ and [PubChem](https://pubchem.ncbi.nlm.nih.gov/) ^[@ref-5]^ (a few exceptions are specified in the original data article ^[@ref-1]^). Compound structures are represented as SMILES ^[@ref-6]^ strings or SD files ^[@ref-7]^. Activity information and other (data set-dependent) annotations are provided in the individual data files. For software tools (written in different languages), the source code is also made available.

Data description
================

[Table 1](#T1){ref-type="table"} provides the updated list and classification of all freely available data sets and programs. Entries were organized according to the following scientific subject areas: data sets for structure-activity relationship (SAR) and structure-selectivity relationship (SSR) analysis, SAR visualization (SAR_VZ), and virtual screening via similarity searching or machine learning (VS_ML). In addition, the programs are provided separately (PROG). Data sets and programs are contained in separate ZENODO deposition sets with a unique reference. Three matched molecular pair (MMP)-based data sets also included in our update have recently been reported and described in detail ^[@ref-8]^. Entries 1--30 in [Table 1](#T1){ref-type="table"} represent the data sets and programs that we initially provided *via* our website ^[@ref-1]^ and entries 31--43 represent new data sets. In the following, the new data sets are described:

###### Data sets and programs.

  --------------------------------------------------------------------------------------------------------------------------------------------------------
  Entry            Year   Subject area\   Description
                          index label     
  ---------------- ------ --------------- ----------------------------------------------------------------------------------------------------------------
  1 ^[@ref-9]^     2007   VS_ML_1         9 activity classes (AC) with increasing structural diversity

  2 ^[@ref-9]^     2007   VS_ML_2         \~1.44 million ZINC compounds used for various virtual screening trials

  3 ^[@ref-10]^    2007   PROG_1          Molecular similarity histogram filtering

  4 ^[@ref-11]^    2007   SSR_1           4 SD files with 26 selectivity sets; compounds are annotated with selectivity values for different targets

  5 ^[@ref-12]^    2008   SSR_2           7 compound selectivity sets containing 267 biogenic amine GPCR antagonists

  6 ^[@ref-13]^    2008   SSR_3           18 selectivity sets for targets from 4 families

  7 ^[@ref-14]^    2008   VS_ML_3         25 sets of compounds of increasing complexity and size

  8 ^[@ref-15]^    2009   VS_ML_4         242 hERG inhibitors

  9 ^[@ref-16]^    2009   SSR_4           243 ionotropic glutamate ion channel antagonists

  10 ^[@ref-17]^   2009   PROG_2          Combinatorial analog graph (CAG) program with a sample set consisting of 51 thrombin inhibitors

  11 ^[@ref-18]^   2009   VS_ML_5         20 AC from the literature and 15 AC from the Molecular Drug Data Report

  12 ^[@ref-19]^   2010   VS_ML_6         8 AC

  13 ^[@ref-20]^   2010   PROG_3          Program to generate target selectivity patterns of scaffolds

  14 ^[@ref-21]^   2010   PROG_4          Multi-target CAGs (see also entry 10) with a sample set containing 33 kinase inhibitors

  15 ^[@ref-22]^   2010   PROG_5          SARANEA

  16 ^[@ref-23]^   2010   PROG_6          3D activity landscape program with a sample set containing 248 cathepsin S inhibitors

  17 ^[@ref-24]^   2010   SAR_1           2 sets of MMPs from BindingDB and ChEMBL

  18 ^[@ref-25]^   2010   PROG_7          Similarity-potency tree (SPT) program with a sample set containing 874 factor Xa inhibitors

  19 ^[@ref-26]^   2010   VS_ML_7         17 target-directed compound sets; each set contains a minimum of 10 distinct scaffolds and each\
                                          scaffold represents 5 compounds

  20 ^[@ref-27]^   2011   SAR_VZ          10,489 malaria screening hits

  21 ^[@ref-28]^   2011   SAR_2           458 target-based sets with scaffolds and scaffold hierarchies

  22 ^[@ref-29]^   2011   SAR_VZ          4 sets of compounds active against 3 or 4 targets

  23 ^[@ref-30]^   2011   SAR_VZ          881 factor Xa inhibitors

  24 ^[@ref-31]^   2011   VS_ML_8         50 AC prioritized for similarity searching

  25 ^[@ref-32]^   2011   VS_ML_9         25 data sets from successful ligand-based virtual screening applications

  26 ^[@ref-33]^   2011   SAR_3           26 conserved scaffolds in activity profile sequences of length 4

  27 ^[@ref-34]^   2011   PROG_8          Scaffold distance function

  28 ^[@ref-35]^   2011   SAR_4           2 sets of compounds with multiple K ~i~ or IC ~50~ measurements against the same targets that differed within\
                                          1 order of magnitude

  29 ^[@ref-36]^   2012   SAR_VZ          4 AC

  30 ^[@ref-37]^   2012   SAR_5           5 sets of different types of activity cliffs

  31 ^[@ref-38]^   2012   VS_ML_10        50 AC for scaffold hopping analysis

  32 ^[@ref-39]^   2012   SAR_6           61 AC consisting of SAR transfer series with regular potency progression

  33 ^[@ref-40]^   2013   SAR_7           4 activity measurement type-dependent sets of scaffolds

  34 ^[@ref-41]^   2013   VS_ML_11        2 multi-target compound sets

  35 ^[@ref-42]^   2013   VS_ML_12        4 multi-target compound sets and 3 multi-mechanism sets

  36 ^[@ref-43]^   2013   SAR_8           2337 compound series matrices

  37 ^[@ref-44]^   2013   SAR_9           128 AC containing ≥100 compounds with K ~i~ values

  38 ^[@ref-45]^   2014   SAR_10          30,452 and 45,607 target-based MMS with K ~i~ and IC ~50~ values, respectively

  39 ^[@ref-46]^   2014   SAR_11          221 drug-unique scaffolds

  40 ^[@ref-47]^   2014   SAR_12          92,734 MMPs based upon retrosynthetic rules for 435 AC

  41 ^[@ref-8]^    2014   SAR_13          20,073 and 25,297 MMP-based activity cliffs with K ~i~ and IC ~50~ values, respectively

  42 ^[@ref-8]^    2014   SAR_14          4 activity measurement type-dependent sets of SAR transfer series with approximate or regular\
                                          potency progression

  43 ^[@ref-8]^    2014   SAR_15          169,889 and 240,322 transformation size-restricted MMPs based upon retrosynthetic rules with K ~i~ and\
                                          IC ~50~ values, respectively
  --------------------------------------------------------------------------------------------------------------------------------------------------------

Data entries are organized according to scientific subject areas: structure-activity relationship (SAR) and structure-selectivity relationship (SSR) analysis, SAR visualization (SAR_VZ), virtual screening *via* similarity searching or machine learning (VS_ML), and programs (PROG). References in the Entry column provide the original publication introducing the program and/or data set. Program entries are described in more detail in Table 2 of our original data article ^[@ref-1]^. The new compound data sets 31--43 are discussed in the text. Programs and data sets reported herein have been separately deposited in ZENODO for access and download.

Entry 31
--------

50 compound activity classes (AC) are prioritized for the evaluation of scaffold hopping potential in ligand-based virtual screening ^[@ref-38]^. These AC contain the largest proportion of scaffold pairs with largest chemical inter-scaffold distances ^[@ref-38]^ that can be derived from current bioactive compounds and hence present challenging test cases for scaffold hopping analysis.

Entry 32
--------

596 SAR transfer series with regular potency progression (SAR-TS-RP) are extracted from 61 AC ^[@ref-39]^. Each SAR-TS-RP represents two compound series with different core structures and pairwise corresponding substitutions that yield comparable potency progression against a given target. These series provide a knowledge base for the analysis and prediction of SAR transfer events.

Entry 33
--------

Four sets of molecular scaffolds (with each scaffold representing more than ten compounds) are provided that are active against a single target (ST), multiple targets from the same family (SF), or multiple targets from different families (MF) ^[@ref-40]^. Data sets are separately assembled for different types of potency measurements ( *i.e*., K ~i~ and IC ~50~ values) and provide a resource of scaffolds representing compounds with varying degrees of target promiscuity.

Entry 34
--------

Two multi-target compound data sets consist of confirmed screening hits ^[@ref-41]^. Each set contains compounds with single-, dual-, and triple-target activity, or no activity. These data provide test cases for machine learning or other approaches to differentiate between compounds with overlapping yet distinct activity profiles.

Entry 35
--------

Four multi-target compound data sets are provided ^[@ref-42]^. Each set contains compounds tested in three different assays. Compounds are organized into eight different subsets according to their activity profiles, *i.e.*, single-, dual-, and triple-target activity, or no activity. In addition, three multi-mechanism compound sets are designed ^[@ref-42]^. In the latter case, compounds are organized into four subsets according to their mechanism-of-action. These data sets also represent test cases for machine learning to distinguish compounds with different activity profiles or mechanisms.

Entry 36
--------

2337 non-redundant compound series matrices (CSMs) are generated covering compounds active against a wide spectrum of targets ^[@ref-43]^. Each matrix contains at least two analogous matching molecular series (MMS) with structurally related yet distinct cores. A matrix consists of known active compounds and structurally related virtual compounds and hence provides suggestions for compound design.

Entry 37
--------

128 target-based data sets are assembled that consist of at least 100 compounds with precisely specified equilibrium constants (K ~i~ values) below 1 µM for human targets ^[@ref-44]^. These high-confidence activity data sets provide a sound basis for SAR exploration.

Entry 38
--------

30,452 and 45,607 target-based MMS with K ~i~ and IC ~50~ values, respectively, are extracted from bioactive compounds ^[@ref-45]^.

Entry 39
--------

221 scaffolds are identified that only occur in approved drugs but are not found in currently available bioactive compounds ^[@ref-46]^. Accordingly, these scaffolds have been termed drug-unique scaffolds.

Entry 40
--------

92,734 MMPs are generated from 435 AC on a basis of retrosynthetic rules ^[@ref-47]^. These MMPs consider chemical reaction information and should be useful for practical medicinal chemistry applications.

Entry 41
--------

20,073 and 25,297 MMP-based activity cliffs ( *i.e.* pairs of structurally analogous compounds with an at least 100-fold difference in potency) are extracted from specifically active compounds based upon K ~i~ and IC ~50~ values, respectively ^[@ref-8]^. The MMP-based activity cliffs provide a large knowledge base for SAR analysis.

Entry 42
--------

157 and 513 MMP-based SAR transfer series with approximate potency progression plus 60 and 322 SAR transfer series with regular potency progression based upon K ~i~ and IC ~50~ values, respectively, are isolated from bioactive compounds. These transfer series are active against individual targets ^[@ref-8]^. Similar to MMP-based activity cliffs, SAR transfer series provide a resource for SAR analysis and compound design.

Entry 43
--------

169,889 and 240,322 transformation size-restricted MMPs based upon retrosynthetic rules with K ~i~ and IC ~50~ values, respectively, are systematically extracted from available AC ^[@ref-8]^. Different from the retrosynthetic rule-based MMPs presented above, applied transformation size-restrictions ensure that chemical changes distinguishing compounds in pairs are small.

Summary
=======

Herein we have provided an updated release of data sets and programs for chemoinformatics and medicinal chemistry that we make freely available. In total, 13 new data sets are introduced. Transferring all data entries in an organized form to the ZENODO platform makes them easily accessible. We hope that our current release might be of interest and helpful to many investigators in academia and the pharmaceutical industry.

Data availability
=================

ZENODO: Programs for chemoinformatics and computational medicinal chemistry, doi: [10.5281/zenodo.8451](http://dx.doi.org/10.5281/zenodo.8451) ^[@ref-48]^.

ZENODO: Data sets for chemoinformatics and computational medicinal chemistry, doi: [10.5281/zenodo.8455](http://dx.doi.org/10.5281/zenodo.8455) ^[@ref-49]^.

We are grateful to current and former members of our research group who have contributed to the development of the data sets and programs reported herein.
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